Insys valuation could be $4 lower on Subsys exclusion, says Wells Fargo After another research firm stated that Insys' (INSY) Subsys would be placed on Express Scripts' (ESRX) list of excluded drugs, Wells Fargo estimates that such a development could reduce Insys' valuation by about $4. The firm notes that the stock fell $4.16 on July 31 and August 1. It keeps an Outperform rating on the shares.
Express Scripts CEO says Gilead relationship 'important' going forward Express Scripts (ESRX) CEO George Paz at the J.P. Morgan Healthcare Conference said his company's relationship with Gilead (GILD) is "important" going forward. Paz said his company's goal is not to exclude drugs. He continues to discuss Express Scripts's deal with AbbVie (ABBV) and the company's goal of saving clients money with regards to healthcare costs.
Insys Therapeutics to initiate five Phase III trials in FY15 Insys Therapeutics announced progress and expected milestones for multiple projects in its pipeline of innovative supportive care and therapy products and candidates. The company intends to submit a New Drug Application to the FDA and to advance five programs into Phase III clinical trials in 2015.